Katherine Stueland sold $1.0M of WGS
CHIEF EXECUTIVE OFFICER at GeneDx Holdings Corp.. 10,501 shares at an average of $97.61, traded Sep 16, 2026, filed Sep 18, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.0M at market
- 0Share of holdings soldSold 8.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689575-26-000032, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | MOption exercise Class A Common Stock | +18,750 | $0.00 | $0 | 125,977 | 27 d ago |
| Sep 16, 2026 | SOpen-market sale Class A Common Stock | -1,648 | $94.26 | $155k | 124,329 | 27 d ago |
| Sep 16, 2026 | SOpen-market sale Class A Common Stock | -148 | $95.41 | $14k | 124,181 | 27 d ago |
| Sep 16, 2026 | SOpen-market sale Class A Common Stock | -1,525 | $96.90 | $148k | 122,656 | 27 d ago |
| Sep 16, 2026 | SOpen-market sale Class A Common Stock | -4,141 | $98.27 | $407k | 118,515 | 27 d ago |
| Sep 16, 2026 | SOpen-market sale Class A Common Stock | -3,039 | $99.00 | $301k | 115,476 | 27 d ago |
| Sep 16, 2026 | MOption exercise Restricted Stock Unitderivative | -18,750 | $0.00 | $0 | 37,500 | 27 d ago |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 28Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $227k 3,729 shares | -9% | |
| 38Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $638k 10,501 shares | -9% | |
| 23Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $68k 1,266 shares | -3% | |
| 30Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $196k 3,639 shares | -4% | |
| 56Moderate | WGSbuy GeneDx Holdings Corp. | Casdin Capital, LLC director, owner | $11M 200,000 shares | +6% | |
| 15Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $19k 369 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.